• www.IBN-is.com
  • www.nanotoday-conference.com

A*STAR Outstanding Publications Award 2009, 2010, 2012, 2013 and 2014
A*STAR Patent Power Award 2009 and 2010
Singapore HEALTH Award (Platinum) 2012, (Gold) 2008 and 2010

ISO Certified (ISO 9001:2008)

OHSAS Certified (SS 506 Part 1:2009/ BS OHSAS 18001:2007



IBN Develops Green Tea-Based ‘Missiles’ to Kill Cancer Cells More Effectively

The IBN research team (from right to left): Dr Susi Tan, Dr Motoichi Kurisawa, Prof Jackie Y. Ying, Dr Shujun Gao,
Dr Joo Eun Chung and Ms Nunnarpas Yongvongsoontorn.

October 6, 2014 – Green tea has long been known for its anti-oxidant, anti-cancer, anti-aging and anti-microbial properties. A group of researchers from the Institute of Bioengineering and Nanotechnology (IBN) of A*STAR has taken the health benefits of green tea to the next level by using one of its ingredients to develop a drug delivery system, which kills cancer cells more efficiently.

A key ingredient in green tea, epigallocatechin gallate (EGCG), is an antioxidant which is known to have therapeutic applications in the treatment of many disorders including cancer.

Using EGCG, IBN researchers have successfully engineered nanocarriers that can deliver drugs and kill cancer cells more efficiently. Their work was published recently in the leading journal Nature Nanotechnology

Read more.

Nano Today on World’s Top 5 List in Three Journal Categories
Singapore-based journal records its highest impact factor of 18.432

August 13, 2014 – Singapore-based Nano Today journal has received a record high impact factor of 18.432 in 2013, up from 17.689 in 2012, according to the Journal Citation Reports® published by Thomson Reuters last month. The scientific journal is one of the highest impact publications across nanoscience and nanotechnology, materials science and chemistry.

Nano Today ranks 2nd among 73 journals in the Nanoscience and Nanotechnology category, 4th out of 251 journals in Materials Science (Multidisciplinary), and 5th out of 148 journals in Chemistry (Multidisciplinary). Nano Today is also the only Asia-based journal among the top 5 journals in these disciplines.

Nano Today is committed towards furthering the latest advances in the multidisciplinary field of nanoscience and nanotechnology, and I am delighted that it is recognized for publishing high-impact and high-quality articles. The journal’s high citation illustrates the importance of our papers in this competitive, rapidly evolving field. I would like to thank our readers, authors, reviewers, Editorial Advisory Board and our Managing Editor Noreena AbuBakar for their strong support and contributions to the journal’s success,” said Professor Jackie Y. Ying, Editor-in-Chief of Nano Today, who is also the Executive Director of the Institute of Bioengineering and Nanotechnology, Singapore.

Read more.

Taking the Guesswork out of Cancer Therapy
New molecular test kit predicts patient’s survival and drug response

Some members of the research team (clockwise from bottom left): IBN Postdoctoral Fellows Dr. Yukti Choudhury and Dr. Xiaona Wei, SGH Dept. of Pathology, Head and Senior Consultant, Prof. Tan Puay Hoon, NCCS Consultant Dr. Ravindran Kanesvaran, IBN Team Leader and Principal Research Scientist Dr. Min-Han Tan.

August 1, 2014 – Researchers and doctors at the Institute of Bioengineering and Nanotechnology (IBN), Singapore General Hospital (SGH) and National Cancer Centre Singapore (NCCS) have co-developed the first molecular test kit that can predict treatment and survival outcomes in kidney cancer patients. This breakthrough was recently reported in European Urology, the world’s top urology journal.

According to IBN Executive Director Professor Jackie Y. Ying, “By combining our expertise in molecular diagnostics and cancer research, we have developed the first genetic test to help doctors prescribe the appropriate treatment for kidney cancer patients based on their tumor profile.”

Dr. Min-Han Tan, who is IBN Team Leader and Principal Research Scientist and a visiting consultant at the Division of Medical Oncology NCCS, shared his motivation, “As a practicing oncologist, I have cared for many patients with kidney cancer. I see the high costs of cancer care, the unpredictable outcomes and occasional futility of even the best available drugs. This experience inspired our development of this assay to improve all these for patients.”

Read more.


IBN in the News

Nano Missile Fights Cancer with Green Tea
AsiaOne, 21 Oct 2014

Nano Missile Fights Cancer with Green Tea
Sunday Times, 19 Oct 2014

Researchers Develop Green Tea-Based 'Missiles' to Kill Cancer Cells More Effectively
PhysOrg, 08 Oct 2014

More News   


18 Nov
IBN Seminar Series: Drug Resistance and the Microenvironment: Strategies to Improve the Clinical Benefit from Chemotherapy by Dr. Ian Tannock, Princess Margaret Cancer Centre and University of Toronto, Canada

8 Dec - 9 Dec
2nd IBN International Symposium – Nanomedicine and Nanoassays

Event Calendar   


NEW! Self-Assembled Micellar Nanocomplexes Comprising Green Tea Catechin Derivatives and Protein Drugs for Cancer Therapy
Nature Nanotechnology, (2014)
DOI: 10.1038/nnano.2014.208.
(IF: 33.265) article

NEW! Transition Metal Complex Catalyzed Carboxylation Reactions with Carbon Dioxide
Coordination Chemistry Reviews, (2014)
DOI: 10.1016/j.ccr.2014.09.002.
(IF: 12.098) article

NEW! Sustained Release of Bupivacaine for Post-Surgical Pain Relief Using Core–Shell Microspheres
Journal of Materials Chemistry B, (2014)
DOI: 10.1039/C4TB00948G.
(IF: 6.626) article



Research Positions

Corporate Administration Positions

Institute of Bioengineering and Nanotechnology   31 Biopolis Way, The Nanos, #04-01, Singapore 138669   Tel: +65 6824 7000   Fax: +65 6478 9080   Email: enquiry@ibn.a-star.edu.sg   |   View IBN Privacy Statement